DyAnsys in the News

GENÈVE, 12 juin 2018 /PRNewswire/ -- DyAnsys Europe SARL a annoncé que sa société mère, DyAnsys Inc., a obtenu l'autorisation de la Food and Drug Administration américaine pour un dispositif de neurostimulation auriculaire destiné à traiter les symptômes du sevrage aux opioïdes sans narcotiques...

Drug Relief

GENF, 12. Juni 2018 /PRNewswire/ -- DyAnsys Europe SARL hat bekannt gegeben, dass seine Muttergesellschaft, DyAnsys Inc., die Zulassung der U. S. Food and Drug Administration für ein aurikuläres Neurostimulationsgerät zur Behandlung der Symptome von Opioidentzug ohne Betäubungsmittel erhalten...

Drug Relief wearable device

GINEBRA, 12 de junio de 2018 /PRNewswire/ -- DyAnsys Europe SARL ha anunciado que su empresa matriz, DyAnsys Inc., cuenta con la aprobación de la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) para un dispositivo de neuroestimulación auricular que trata los síntomas del...

San Mateo, Ca -- DyAnsys Inc. announced that the U.S. Food and Drug Administration has cleared its auricular neurostimulation device, Drug Relief®, to be used as an aid to reduce the symptoms of opioid withdrawal without narcotics.

 

Drug Relief® is available now for providers to...

Advanced Medical Diagnostic and Monitoring Systems

Interview conducted by:
Lynn Fosse, Senior Editor, CEOCFO Magazine, Published – June 29, 2015

CEOCFO: Mr. Nageshwar, what is the concept behind DyAnsys?
Mr. Nageshwar: We established the company based on measuring medical...